More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
An AI startup in the neuro-oncology space has received the government’s go-ahead to market software for analyzing certain fast-growing brain tumors on MRI.
If generalizable AI models are to meaningfully contribute to precision cancer care, they’ll need to incorporate not only imaging data but also digitalized clinical notes, biomarker assays and monitor readouts.
Could wearables help AFib patients take fewer blood-thinning medications and reduce their risk of stroke? The team behind a new seven-year analysis hopes to find out.
Researchers have shared an updated analysis of the SMART-CHOICE study, focusing on major adverse cardiac and cerebrovascular events—as well as bleeding events—among PCI patients after three years.
Clinicians treating COVID-19 patients who have transplanted lungs and lower airway infection should order molecular testing in addition to, or regardless of, imaging findings.
Previously, CMS determined that coverage for patients receiving treatment was dependent on their being enrolled in a CMS-approved clinical trial under coverage with evidence development (CED).
